Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02435563
Recruitment Status : Completed
First Posted : May 6, 2015
Last Update Posted : February 7, 2017
Sponsor:
Information provided by (Responsible Party):
Jules Desmeules, University Hospital, Geneva

Brief Summary:

Ticagrelor is a new generation antiplatelet agent with higher efficacy as compared to clopidogrel and prasugrel in treatment of patients with moderate and high ischemic risks. Ticagrelor is active as such and its hepatic metabolism by CYP3A generates also an active metabolite. Because of the remarkable progress in HIV therapies the number of older age patients is on the rise, requiring adequate cardiovascular treatment. Since frontline HIV therapies include ritonavir, a strong inhibitor of CYP3A enzyme, ticagrelor is contraindicated in these patients because of the expected interaction and bleeding risk. A lower efficacy of clopidogrel and prasugrel, which are both pro-drugs, in the presence of ritonavir has been already demonstrated. Therefore, administration of a lower dose of ticagrelor may be a good alternative in HIV patients in order to lessen the impact of this pharmacokinetic interaction. The aim of this study is to adjust the dose of ticagrelor in case of co-treatment with ritonavir to achieve the same pharmacokinetic profile as administered alone using a physiologically-based pharmacokinetic (PBPK) model.

As the first step, a pharmacokinetic (PK) model for ticagrelor and its active metabolite will be created based on available in vitro and in vivo parameters in healthy volunteers.

An open-label, 2 sessions cross over study will be conducted with 20 healthy male volunteers at Clinical Research Center (CRC) of Geneva University Hospitals (HUG). During the first session of the clinical trial, a single dose 180 mg ticagrelor will be administered to the volunteers and obtained pharmacokinetic data will be fitted into the model for optimization. Thereafter a simulated trial by the Simcyp® simulator in presence of a single dose 100 mg ritonavir will allow evaluating the impact of CYP3A inhibition on the concentration-time profile of ticagrelor and its active metabolite. The necessary dose of ticagrelor to minimize the magnitude of this interaction will be calculated. This new dose will be co-administered with ritonavir in the same volunteers during the second session of the clinical trial. The purpose is to obtain the same PK profile with single dose of 180 mg ticagrelor administered alone and with an adapted dose of ticagrelor co-administered with a single dose 100 mg ritonavir. Moreover, the pharmacodynamic effect of ticagrelor will be measured in both sessions of the clinical trial using two specific platelet function tests: the VAsodilator-Stimulated Phosphoprotein assay (VASP) and VerifyNow® P2Y12. With the same PK profile, the same pharmacodynamic activity is expected. The modulation of activity of CYP3A and P-gp by ritonavir will be also monitored using micro dose midazolam and fexofenadine as probe substrates.

The purpose of this study is to use the Simcyp® Simulator mechanistic PBPK modeling to broaden the application field of ticagrelor, especially in HIV patients. Since PK models are often created after clinical observations, the prospective aspect of this study is of particular value as the model will be first created and then applied to an unknown clinical scenario.


Condition or disease Intervention/treatment Phase
Healthy Drug: ticagrelor 180 mg administrated alone Drug: Ticagrelor adjusted dose + ritonavir 100mg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Dose Adaptation to Offset the Pharmacokinetic Interaction Between Ticagrelor and Ritonavir in Healthy Volunteers by Population-based PK Modeling (Simcyp®)
Study Start Date : August 2014
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Experimental: Ticagrelor 180 mg
Single dose of 180mg ticagrelor administered orally
Drug: ticagrelor 180 mg administrated alone
Experimental: Ticagrelor adjusted dose+ritonavir 100mg
adpated dose of ticagrelor calculated after PK modelisation with the Simcyp® simulator administered simultaneously with 100 mg ritonavir
Drug: Ticagrelor adjusted dose + ritonavir 100mg



Primary Outcome Measures :
  1. Change in AUC of ticagrelor and its metabolite from baseline [ Time Frame: 30 min 1hr 2hr 3hr 4hr 6hr 8hr 24hr ]
    Venous blood samples will be taken to assess the baseline pharmacokinetic parameters of ticagrelor and its metabolite, prior to ticagrelor administration (time zero) and at the following post dosage times: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours


Secondary Outcome Measures :
  1. Measure of the pharmacodynamic response to ticagrelor by two platelet reactivity tests VASP and VerifyNow® P2Y12 [ Time Frame: 4hr ]
    4 hours after administration of ticagrelor the pharmacodynamic, response of ticagrelor will be assessed by the VAsodilator-Stimulated Phosphoprotein Assay (VASP) and VerifyNow® P2Y12 tests

  2. Change in P-gp phenotyping from baseline (0 min) [ Time Frame: 30 min 1hr 2hr 3hr 4hr 6hr 8hr 24hr ]
    Venous blood samples will be taken to assess the P-gp phenotyping, prior to fexofenadine administration (time zero) and at the following post dosage times: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours

  3. Change in CYP3A4 phenotyping from baseline (0 min) [ Time Frame: 1hr ]
    Venous blood samples will be taken to assess the CYP3A4 phenotyping, prior to midazolam administration (time zero) and at the following post dosage time: 1 hour



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteers
  • Aged between 18 and 60 years
  • BMI between 18 and 27
  • Understanding of French language and able to give an inform consent.

Exclusion Criteria:

  • Hypersensitivity to ticagrelor or ritonavir or any constituents of the tablets
  • Concomitant diseases
  • Smokers (> 20 cigarettes per day)
  • Intake of any drug or food (grapefruit) that is metabolized by or can affect CYP3A or P-glycoprotein activity within the last 10 days
  • Pathologies or drugs associated with an increased bleeding risk such as aspirin, non-steroidal anti-inflammatory drugs, steroids and serotonin reuptake inhibitors
  • Bleeding familial history or antecedent or hemorrhagic disease
  • Previous or active gastro-intestinal ulcer
  • Alteration of hepatic tests (ASAT>100 U/l, ALAT >100 U/l, GGT >80 U/l, BILI > 50 μmol/l)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02435563


Locations
Layout table for location information
Switzerland
Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4
Genève, Switzerland, 1211
Sponsors and Collaborators
University Hospital, Geneva
Layout table for additonal information
Responsible Party: Jules Desmeules, Dr, University Hospital, Geneva
ClinicalTrials.gov Identifier: NCT02435563    
Other Study ID Numbers: 13-182
First Posted: May 6, 2015    Key Record Dates
Last Update Posted: February 7, 2017
Last Verified: February 2017
Keywords provided by Jules Desmeules, University Hospital, Geneva:
Anti-HIV Agents
cardiovascular agents
drug interactions
Additional relevant MeSH terms:
Layout table for MeSH terms
Ritonavir
Ticagrelor
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs